Monday, February 6, 2012

Biotech Patents: Equivalency and Exclusions Under European and U.S. Patent Law

May 28, 2010 by biotechconnection.com · Leave a Comment 

Product DescriptionThere is no denying that biotechnological inventions in some ways have challenged the legal system of providing market exclusivity through patents. First of all, their patentability has been questioned. Furthermore, the scope of protection conferred to these inventions is obscured because of the difficulty of applying legal concepts to [...]

Walk in the park: Don’t forget to search for blooms under the ‘umbrella’

May 17, 2010 by biotechconnection.com · Leave a Comment 

Walk in the park: Don’t forget to search for blooms under the ‘umbrella’
When I was little, the tales I read told me that toadstools were in the forest to provide chairs for the fairies that, I supposed, lived in abundance in the northern woods.
Read more on This Week Olentangy

Sector movers: Resource stocks under pressure

May 10, 2010 by biotechconnection.com · Leave a Comment 

Sector movers: Resource stocks under pressure
LONDON (SHARECAST) – Miners BHP Billiton and Xstrata have reacted angrily to the Australian government’s plans to introduce a new resource rent tax and say the levy may jeopardise future investments.
Read more on ShareCast

Journalists Under Fire: Vietnam and Iraq

March 27, 2010 by biotechconnection.com · 3 Comments 

Photographers Catherine Leroy, David Leeson and Don mccullin along with columnist Jonathan Schell and television correspondent Mike Cerre share their experiences and expressions of war from the fields of 1960’s Vietnam and Iraq today. Presented by the Graduate School of Journalism at UC Berkeley. Series: “UC Berkeley Graduate School of Journalism presents” [5/2005] [Public Affairs] [...]

Seattle Genetics Achieves Milestone under Antibody-Drug Conjugate Collaboration with Genentech

March 3, 2010 by biotechconnection.com · Leave a Comment 

Seattle Genetics Achieves Milestone under Antibody-Drug Conjugate Collaboration with Genentech
BOTHELL, Wash.—-Seattle Genetics, Inc. announced today that it has achieved a milestone under its antibody-drug conjugate collaboration with Genentech, Inc., a wholly owned member of the Roche Group .
Read more on Business Wire via Yahoo! Finance

Next Page »